Physician profile
Samuel Okoh
NPI 1730381252
$3,155.38
in general payments reported to CMS, 2019-2025
13 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $153 · 2021: $77.42 · 2022: $72.33 · 2023: $125 · 2024: $2,282 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,701 · Food and Beverage: $929 · Education: $51.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,701.21 |
| Food and Beverage | $928.90 |
| Education | $51.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,142.11 | 2024 | Wavewriter Alpha Prime 16 |
| Otsuka America Pharmaceutical, INC. | $267.23 | 2019-2020 | |
| Amgen INC. | $233.16 | 2024-2025 | Krystexxa |
| Horizon Therapeutics Plc | $187.99 | 2020-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $76.81 | 2025 | Benlysta |
| Travere Therapeutics, INC. | $53.56 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $33.48 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.62 | 2022-2023 | |
| Novo Nordisk INC | $32.27 | 2024 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $31.17 | 2023-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $25.72 | 2019 | |
| Fresenius USA Marketing, INC. | $23.60 | 2023 | Korsuva, Velphoro |
| Ardelyx, INC. | $15.66 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Okoh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.